The sNDA filing in H1 2027 is the next key catalyst. Monitor the investor day on December 9, 2026 for commercial launch strategy and peak sales estimates for NIU. The breadth of efficacy data suggests potential for a broad label across NIU subtypes, which could drive significant upside versus current expectations.
Price Chart
Executive Summary
Roivant and its subsidiary Priovant announced positive Phase 3 results for brepocitinib in non-infectious uveitis (NIU). The CLARITY-1 and CLARITY-2 trials met the primary endpoint and all key secondary endpoints with high statistical significance, showing brepocitinib 45 mg once-daily achieved a median time to treatment failure >48 weeks vs ~12 weeks on placebo. Priovant intends to file an sNDA in the first half of 2027, positioning brepocitinib as a potential new standard of care for NIU.
Key Facts
- Brepocitinib 45 mg once-daily met the primary endpoint (time to treatment failure) in both CLARITY-1 and CLARITY-2 Phase 3 trials for NIU (p<0.0001).
- Median time to treatment failure for brepocitinib was >48 weeks vs ~12 weeks on placebo in both studies.
- Pooled across studies, 62% of brepocitinib patients achieved steroid-free quiescence at Week 48 vs 20% on placebo (p<0.0001).
- Resolution of macular edema at Week 48: 42% of eyes on brepocitinib vs 4.8% on placebo (pooled, p<0.0001).
- Safety profile consistent with prior brepocitinib trials; only 3% discontinued due to an AE.
- Priovant intends to file an sNDA for brepocitinib in NIU in the first half of calendar year 2027.
- NIU affects an estimated 70,000 to 190,000 adults in the United States.
Financial Impact
No financial figures provided in the filing. The positive Phase 3 data supports a potential new label expansion for brepocitinib into a sizable orphan indication (70k-190k US patients), which could meaningfully expand the commercial opportunity for Roivant's LISRAYA franchise.
Risk Factors
- Regulatory risk: FDA may require additional data or raise concerns about the safety profile of a JAK inhibitor in a non-life-threatening ocular indication.
- Commercial risk: NIU is a niche indication with established steroid and biologic alternatives; adoption may be slower than anticipated.
- Competitive risk: Other systemic therapies (e.g., adalimumab) are already approved for NIU; brepocitinib must demonstrate clear differentiation in real-world practice.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-040332 |
| Document: ef20084121_8k.htm | 0001140361-26-040332 |
| Document: 0001140361-26-040332-index-headers.html | 0001140361-26-040332 |
| Document: 0001140361-26-040332-index.html | 0001140361-26-040332 |
| Document: 0001140361-26-040332.txt | 0001140361-26-040332 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $36.04 | awaiting T+20 | — | $36.05 (+0.03%) |
Oct 21, 2026 6d ago | 8-K | $36.80 | awaiting T+20 | — | $36.05 (−2.04%) |
Oct 5, 2026 22d ago | Insider Cluster | $35.53 | awaiting T+20 | — | $36.05 (−1.46%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 1, 2026 7w ago | Insider Cluster | $34.18 $36.57 | ▲ +6.99% | ▲ +7.32% | $36.05 (+5.47%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.05 (−4.07%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.05 (−4.07%) |
Aug 26, 2026 8w ago | Press Release | $36.75 $38.99 | ▲ +6.10% | ▲ +4.89% | $36.05 (−1.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers